Vivos Inc (RDGL)

[bdvest]

COMPANY OVERVIEW by redchip.com
https://www.redchip.com/company/Biotech/RDGL/376/RDGL

Vivos Inc (OTC: RDGL) is engaged in the development of a brachytherapy device for the treatment of cancerous tumors. Brachytherapy uses radiation to destroy tumors by placing a radioactive isotope inside the treatment area. Currently, the company is pursuing FDA approval of its brachytherapy device, RadioGel, initially for the treatment of advanced basal and squamous skin cancers. Concurrently, the Company is pursuing development of veterinary applications for a range of cancers in collaboration with four leading university veterinary hospitals. Veterinary applications should have a faster path to revenue for RDGL, while providing data supporting the safety and therapeutic effectiveness of RadioGel. RDGL’s RadioGel requires no pre-market approval for pet therapy and the Company plans to generate near term revenue from veterinarian clinics and international licensing by 1Q18.

VALUE PROPOSITION
RDGL is in late-stage development of a brachytherapy device for medical and veterinary cancer treatment applications. The Company plans to generate near-term revenue from veterinarian clinics and international licensing while pursuing FDA approval for multiple cancer indications. RDGL’s cancer treatment can disrupt the cancer treatment market, offering the potential upside of a drug with lower cost and shorter approval path of a device. Additionally, companies involved in brachytherapy treatment, such as Elekta AB ($3.5 billion) and Varian Medical Systems ($9.2 billion), provide an idea of valuation potential for RDGL, which represents significant upside from current levels.

INVESTMENT HIGHLIGHTS
Plans to generate near-term revenue from veterinarian clinics and international licensing by 1Q18; RDGL is in late-stage development of a brachytherapy device for medical and veterinary cancer treatment applications

Company has the potential to disrupt the cancer treatment market with lower cost and shorter approval path of a cancer treatment device
Brachytherapy market is expected to reach $245 million by 2018
RDGL’s next-generation radiopharmaceutical therapeutic device uses hydrogel that is liquid at room temperature and solidifies at body temperate and locks in the particles

Company’s RadioGel requires no pre-market approval for pet therapy
Cancer is the leading cause of death for 32% of cats and 50% of dogs over age 10, Treating 10% of pet cancers at $5,000 average per treatment, generates $40 million annual revenue
Currently testing at leading university veterinary programs to demonstrate therapy across multiple indications

Strong leadership and word-class medical advisory board
More than 125 years combined experience; input from Mayo Clinic doctors